Sofosvel is a fixed-dose combination antiviral medicine containing Sofosbuvir and Velpatasvir, used for the treatment of chronic hepatitis C virus (HCV) infection. This combination offers a highly effective, pan-genotypic treatment option, meaning it is active against all major HCV genotypes (1–6). Sofosvel is widely recognized for its high cure rates, excellent tolerability, and simplified once-daily oral dosing.

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, an enzyme essential for viral replication. Velpatasvir is an inhibitor of the HCV NS5A protein, which plays a key role in viral replication and assembly. By targeting two different stages of the HCV life cycle, Sofosvel provides potent viral suppression and helps achieve sustained virologic response (SVR), which is considered a virologic cure.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Sofosvel is indicated for the treatment of:

• Chronic hepatitis C virus infection in adult patients with genotypes 1, 2, 3, 4, 5, or 6.

• Patients with or without compensated liver cirrhosis.

• Selected patients with decompensated cirrhosis, as recommended by a specialist and in combination with other therapies if required.

Therapeutic Class

• Antiviral Agent

• Direct-Acting Antiviral (DAA)

Pharmacology

Sofosbuvir undergoes intracellular metabolism to form its active triphosphate, which inhibits HCV RNA synthesis by incorporation into viral RNA, causing chain termination. Velpatasvir inhibits the NS5A protein, disrupting viral replication and assembly. The dual mechanism ensures broad antiviral activity and minimizes the risk of resistance development.

Both components are well absorbed following oral administration. The pharmacokinetic profile supports once-daily dosing, maintaining effective drug concentrations throughout the treatment period. Viral load reduction typically occurs rapidly after initiation of therapy.

Dosage and Administration

• Sofosvel is taken orally once daily, with or without food.

• The usual treatment duration is 12 weeks, depending on patient characteristics and disease severity.

• Tablets should be swallowed whole and taken at the same time each day.

• Adherence to the full treatment course is essential to achieve optimal treatment outcomes.

Key Benefits

• Pan-genotypic activity against all major HCV genotypes.

• High cure rates with sustained virologic response.

• Simple once-daily oral dosing.

• Well tolerated with a favorable safety profile.

• Effective in patients with or without cirrhosis.

Precautions and Warnings

• Screening for hepatitis B virus (HBV) is recommended before initiating therapy, as reactivation may occur.

• Use with caution in patients with severe renal impairment or decompensated liver disease.

• Potential drug interactions should be reviewed prior to initiation.

• Not recommended during pregnancy unless clearly necessary.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

Common adverse effects may include headache, fatigue, nausea, insomnia, and mild gastrointestinal discomfort. Most side effects are mild and do not require discontinuation of therapy.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Sofosvel provides a reliable and effective treatment solution for chronic hepatitis C, supporting viral eradication, improved liver health, and long-term patient outcomes.